[go: up one dir, main page]

CL2011001088A1 - Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress. - Google Patents

Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress.

Info

Publication number
CL2011001088A1
CL2011001088A1 CL2011001088A CL2011001088A CL2011001088A1 CL 2011001088 A1 CL2011001088 A1 CL 2011001088A1 CL 2011001088 A CL2011001088 A CL 2011001088A CL 2011001088 A CL2011001088 A CL 2011001088A CL 2011001088 A1 CL2011001088 A1 CL 2011001088A1
Authority
CL
Chile
Prior art keywords
piperidine
phenyl
affective
depressive
painful
Prior art date
Application number
CL2011001088A
Other languages
English (en)
Inventor
Robert Chao
Lori Jean Patterson
Miroslav Rapta
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2011001088A1 publication Critical patent/CL2011001088A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)

Abstract

UNA SAL CLORIDRATO CRISTALINA DE 4-(2-2(2, 4, 6-TRIFLUOROFENOXIMETIL)FENIL)PIPERINA, CARACTERIZADO POR VALORES 20 DEL ESPECTRO DE DIFRACCION DE RAYOS X. PROCESO PARA PREPARAR SU FORMA PURIFICADA QUE COMPRENDE LOS SOGUIENTES PASOS A) COMBINAR T-BUTIL ESTER DEL ACIDO 4-(2- METANOSULFONILOXIMETIFENIL)PIPERIDINA -1-CARBOXILICO CON HCI 1.25M EN ETANOL PARA FORMAR UNA MEZCLA, B) AGRFEGAR ETIL ACETATO A LA MEZCLA PARA FORMAR LA SAL CLORHIDRATO CRISTALINA DE LA REINVINDICACION 1, C) AISLAR LA SAL CLORHIDRATO CRISTALINA PARA OBTENER 4-(2-(2, 4, 6-TRIFLUOROFENOXIMETIL)FENIL) PIPERIDINA CON UN 99 % DE PUREZA. SE DESCRIBE UNA COMPOSICION FARMACEUTICA QUE LA COMPRENDE Y SU USO PARA TRATAR UN TRASTORNO DOLOROSO, DEPRESIVO, AFECTIVO, COGNOTIVO, OBESIDAD, SINDROME DE FATIGA CRONICA E INCONTINENCIA URINARIA POR STRESS.
CL2011001088A 2008-11-14 2011-05-12 Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress. CL2011001088A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
CL2011001088A1 true CL2011001088A1 (es) 2011-10-14

Family

ID=41666409

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001088A CL2011001088A1 (es) 2008-11-14 2011-05-12 Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress.
CL2011001093A CL2011001093A1 (es) 2008-11-14 2011-05-13 Compuestos derivados de 4-[2-(2-fluorofenoximetil)fenil]piperidina, inhibidores de la recaptacion de serotonina y norepinefrina; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar el dolor neuropatico, fibromialgia, trastorno depresivo y obesidad entre otras.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2011001093A CL2011001093A1 (es) 2008-11-14 2011-05-13 Compuestos derivados de 4-[2-(2-fluorofenoximetil)fenil]piperidina, inhibidores de la recaptacion de serotonina y norepinefrina; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar el dolor neuropatico, fibromialgia, trastorno depresivo y obesidad entre otras.

Country Status (28)

Country Link
US (23) US8247433B2 (es)
EP (3) EP2358676B1 (es)
JP (6) JP5529150B2 (es)
KR (3) KR101685186B1 (es)
CN (3) CN102216271B (es)
AR (3) AR074350A1 (es)
AU (3) AU2009313949B2 (es)
BR (3) BRPI0921596B1 (es)
CA (3) CA2739992C (es)
CL (2) CL2011001088A1 (es)
CO (2) CO6361988A2 (es)
CY (3) CY1113622T1 (es)
DK (3) DK2358674T3 (es)
ES (3) ES2401224T3 (es)
HR (3) HRP20120897T1 (es)
IL (2) IL212230A (es)
MX (3) MX2011005089A (es)
MY (2) MY151229A (es)
NZ (2) NZ592543A (es)
PL (3) PL2358675T3 (es)
PT (3) PT2358674E (es)
RU (2) RU2503662C2 (es)
SG (1) SG171311A1 (es)
SI (3) SI2358675T1 (es)
SM (3) SMT201200063B (es)
TW (3) TWI443087B (es)
WO (3) WO2010056938A1 (es)
ZA (1) ZA201103495B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358676B1 (en) 2008-11-14 2012-10-10 Theravance, Inc. Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
WO2011133790A2 (en) 2010-04-22 2011-10-27 Theravance, Inc. Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
MY194181A (en) * 2016-08-30 2022-11-17 Theravance Biopharma R&D Ip Llc Compound for use in the treatment of neurogenic orthostatic hypotension
US10640467B2 (en) 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
EP4499096A1 (en) 2022-03-28 2025-02-05 Theravance Biopharma R&D IP, LLC Ampreloxetine for use for treating multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
EP1097137A1 (en) * 1998-07-10 2001-05-09 AstraZeneca AB N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
TR200103147T1 (tr) * 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60324685D1 (de) * 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
SI1635828T1 (sl) * 2003-04-04 2008-08-31 Lundbeck & Co As H Derivati 4-(2-feniloksifenil)-piperidina ali-1,2,3,6-tetrahidropiridina kot inhibitorji ponovnega privzema serotonina
PL1638933T3 (pl) 2003-06-17 2008-10-31 Pfizer Pochodne n-pirolidyn-3-yloamidu jako inhibitory wychwytu zwrotnego serotoniny i noradrenaliny
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
WO2005068447A1 (en) * 2004-01-13 2005-07-28 Pfizer Limited Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-upatke inhibitors
EP1725518A1 (en) * 2004-03-05 2006-11-29 Eli Lilly And Company Pharmaceutical compounds
EA200601798A1 (ru) 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
CA2661187A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
EP2068867A2 (en) * 2006-09-27 2009-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
US7888386B2 (en) 2008-07-24 2011-02-15 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
EP2358676B1 (en) 2008-11-14 2012-10-10 Theravance, Inc. Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
MY194181A (en) * 2016-08-30 2022-11-17 Theravance Biopharma R&D Ip Llc Compound for use in the treatment of neurogenic orthostatic hypotension

Also Published As

Publication number Publication date
US20160184288A1 (en) 2016-06-30
WO2010056939A1 (en) 2010-05-20
RU2011123890A (ru) 2012-12-20
ES2397247T3 (es) 2013-03-05
SI2358674T1 (sl) 2013-04-30
KR20110082085A (ko) 2011-07-15
KR101685186B1 (ko) 2016-12-09
KR101656339B1 (ko) 2016-09-09
IL212452A0 (en) 2011-06-30
US20140045892A1 (en) 2014-02-13
US20230201181A1 (en) 2023-06-29
CA2739992A1 (en) 2010-05-20
ES2396583T3 (es) 2013-02-22
CY1113623T1 (el) 2016-06-22
IL212230A (en) 2014-12-31
US8304432B2 (en) 2012-11-06
HRP20120920T1 (hr) 2013-01-31
CN102209712B (zh) 2016-04-06
CO6361993A2 (es) 2012-01-20
JP5506813B2 (ja) 2014-05-28
KR20110082196A (ko) 2011-07-18
PL2358676T3 (pl) 2013-03-29
CN102216272B (zh) 2014-02-05
DK2358674T3 (da) 2013-04-08
US20130030020A1 (en) 2013-01-31
US10206913B2 (en) 2019-02-19
HRP20120897T1 (hr) 2012-12-31
SMT201200063B (it) 2013-01-14
CA2742105A1 (en) 2010-05-20
AR074350A1 (es) 2011-01-12
CA2739992C (en) 2016-09-20
WO2010056941A1 (en) 2010-05-20
MY151211A (en) 2014-04-30
US20190134019A1 (en) 2019-05-09
KR101656338B1 (ko) 2016-09-09
BRPI0921596B1 (pt) 2021-10-26
US10722504B2 (en) 2020-07-28
CA2742114A1 (en) 2010-05-20
ZA201103495B (en) 2012-01-25
US20100125093A1 (en) 2010-05-20
AU2009313948A1 (en) 2010-05-20
US20190142816A1 (en) 2019-05-16
AR114965A2 (es) 2020-11-11
SMT201300033B (it) 2013-05-06
US20140057944A1 (en) 2014-02-27
DK2358675T3 (da) 2013-01-14
US11596624B2 (en) 2023-03-07
BRPI0921596A2 (pt) 2018-03-20
BRPI0921593B1 (pt) 2021-05-04
US11723900B2 (en) 2023-08-15
BRPI0921593B8 (pt) 2021-05-25
DK2358676T3 (da) 2013-01-14
HK1160452A1 (en) 2012-08-17
US20240316024A1 (en) 2024-09-26
US20200316047A1 (en) 2020-10-08
IL212230A0 (en) 2011-06-30
EP2358674B1 (en) 2013-01-02
MY151229A (en) 2014-04-30
EP2358676B1 (en) 2012-10-10
TWI443087B (zh) 2014-07-01
TWI441810B (zh) 2014-06-21
JP5598798B2 (ja) 2014-10-01
EP2358675A1 (en) 2011-08-24
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
CY1113855T1 (el) 2016-07-27
CN102216271B (zh) 2013-09-25
US10576073B2 (en) 2020-03-03
US10946007B2 (en) 2021-03-16
AU2009313951A1 (en) 2010-05-20
CA2742114C (en) 2016-09-13
US20130030185A1 (en) 2013-01-31
SI2358675T1 (sl) 2013-01-31
PL2358674T3 (pl) 2013-06-28
US20120277438A1 (en) 2012-11-01
EP2358675B1 (en) 2012-10-03
BRPI0921595B8 (pt) 2021-05-25
JP2014101384A (ja) 2014-06-05
CA2742105C (en) 2016-09-13
US9187423B2 (en) 2015-11-17
CY1113622T1 (el) 2016-06-22
US8592596B2 (en) 2013-11-26
TWI461407B (zh) 2014-11-21
JP2012508761A (ja) 2012-04-12
PT2358676E (pt) 2012-12-06
AR074128A1 (es) 2010-12-22
US10226454B2 (en) 2019-03-12
US12239638B2 (en) 2025-03-04
US10034870B2 (en) 2018-07-31
PT2358675E (pt) 2012-12-12
AU2009313948B2 (en) 2015-03-12
US20200000792A1 (en) 2020-01-02
AU2009313951B2 (en) 2015-03-12
US20180055830A1 (en) 2018-03-01
KR20110082197A (ko) 2011-07-18
US8604058B2 (en) 2013-12-10
US10441579B2 (en) 2019-10-15
US8802857B2 (en) 2014-08-12
NZ592413A (en) 2013-02-22
EP2358674A1 (en) 2011-08-24
AU2009313949A1 (en) 2010-05-20
CN102216271A (zh) 2011-10-12
US20180289687A1 (en) 2018-10-11
HRP20130300T1 (hr) 2013-04-30
JP2012508759A (ja) 2012-04-12
TW201022206A (en) 2010-06-16
US20100125141A1 (en) 2010-05-20
US9073859B2 (en) 2015-07-07
NZ592543A (en) 2013-02-22
BRPI0921593A2 (pt) 2015-08-18
MX2011005089A (es) 2011-07-29
JP2014139209A (ja) 2014-07-31
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
US20200316048A1 (en) 2020-10-08
RU2011123875A (ru) 2012-12-20
MX2011005090A (es) 2011-09-06
HK1160448A1 (en) 2012-08-17
TW201024263A (en) 2010-07-01
CL2011001093A1 (es) 2011-09-02
AU2009313949B2 (en) 2015-03-19
CN102216272A (zh) 2011-10-12
US9162982B2 (en) 2015-10-20
US9675599B2 (en) 2017-06-13
SG171311A1 (en) 2011-07-28
BRPI0921595B1 (pt) 2020-10-13
US8304433B2 (en) 2012-11-06
EP2358676A1 (en) 2011-08-24
MX2011005088A (es) 2011-06-01
RU2503662C2 (ru) 2014-01-10
TW201024264A (en) 2010-07-01
JP2012508760A (ja) 2012-04-12
RU2515612C2 (ru) 2014-05-20
PT2358674E (pt) 2013-03-05
US8247433B2 (en) 2012-08-21
CO6361988A2 (es) 2012-01-20
US20140323735A1 (en) 2014-10-30
US10946006B2 (en) 2021-03-16
SMT201200065B (it) 2013-03-08
JP2014098033A (ja) 2014-05-29
PL2358675T3 (pl) 2013-03-29
US20180050024A1 (en) 2018-02-22
CN102209712A (zh) 2011-10-05
US20160022660A1 (en) 2016-01-28
SI2358676T1 (sl) 2013-01-31
EP2358675B9 (en) 2019-09-11
HK1160449A1 (en) 2012-08-17
JP5529150B2 (ja) 2014-06-25
ES2401224T3 (es) 2013-04-17

Similar Documents

Publication Publication Date Title
CL2011001088A1 (es) Sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina; composicion farmaceutica que la comprende; y uso para tratar un trastorno doloroso, depresivo, afectivo, cognitivo, obesidad, sindrome de fatiga cronica, incontinencia urinaria por stress.
ECSP055601A (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
EA201591978A1 (ru) 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил)- карбамимидоил)пиразин-2-карбоксамид
MX2010009401A (es) Forma cristalina de derivado de fenilamino pirimidina.
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
BR112014009102A2 (pt) compostos químicos
PE20161416A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
MX349159B (es) Derivados deuterados de ivacaftor.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
PE20140966A1 (es) Quinazolincarboxamida azetidinas
AR070701A1 (es) Derivados de fluoroglicosidos aromaticos, medicamentos que comprenden estos compuestos y uso de los mismos para producir un medicamento
CY1112645T1 (el) Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275)
AR083020A1 (es) Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
AR082418A1 (es) Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
BRPI0811245A2 (pt) Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto.
EA201100502A1 (ru) Гликозидные производные и их применения
NZ619257A (en) Ketamine derivatives
BR112013031759A2 (pt) forma cristalina de derivados de indazolil amida para o tratamento de distúrbios mediados pelo receptor de glicocorticoides